LipoScience (FRA:LI0) Total Current Assets : €34.75 Mil (As of Sep. 2014)

View and export this data going back to . Start your Free Trial

What is LipoScience Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. LipoScience's total current assets for the quarter that ended in Sep. 2014 was €34.75 Mil.

LipoScience Total Current Assets Historical Data

The historical data trend for LipoScience's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LipoScience Total Current Assets Chart

LipoScience Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Total Current Assets

11.92

14.20

23.44

41.31

LipoScience Quarterly Data
	Mar11	Jun11	Dec11	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Total Current Assets	Get a 7-Day Free Trial								44.26	41.31	38.02	35.64	34.75

LipoScience Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

LipoScience's Total Current Assets for the fiscal year that ended in Dec. 2013 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	36.189	+	4.249	+	0.164	+	0.709
	=	41.31

LipoScience's Total Current Assets for the quarter that ended in Sep. 2014 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	31.037	+	3.014	+	0.154	+	0.541
	=	34.75

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

LipoScience (FRA:LI0) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

LipoScience's Liquidation Value for the quarter that ended in Sep. 2014 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	31.037	-	18.612	+	0.75 * 3.014	+	0.5 * 0.154
=	14.76

LipoScience Total Current Assets Related Terms

Thank you for viewing the detailed overview of LipoScience's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

LipoScience (FRA:LI0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LipoScience Inc (FRA:LI0) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.liposcience.com

LipoScience Inc was incorporated under the laws of North Carolina in June 1994 under the name LipoMed, Inc. and reincorporated under the laws of Delaware in June 2000. The Company is a clinical diagnostic company into field of personalized diagnostics based on nuclear magnetic resonance technology. The Company's first diagnostic test, the NMR LipoProfile test, is cleared by the U.S. Food and Drug Administration, and directly measures the number of low density lipoprotein, particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. The Company's technology platform combines proprietary signal processing algorithms and NMR spectroscopic detection into a clinical analyzer to identify and quantify concentrations of lipoproteins and, potentially, small molecule metabolites. NMR detectors, or spectrometers, analyze a blood plasma or serum sample by subjecting it to a short pulse of radio frequency energy within a strong magnetic field. The Company currently markets NMR LipoProfile test through a direct sales force in 27 states. The Company competes against companies that offer other methods for measuring lipoproteins. Its competitors include Quest Diagnostics, Berkeley HeartLab, Inc., Atherotech, Inc. and SpectraCell Laboratories. The Company is subject to extensive and frequently changing federal, state and local laws and regulations governing various aspects of its business.

LipoScience (FRA:LI0) Headlines

No Headlines